Candriam S.C.A. Sells 4,400 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Candriam S.C.A. decreased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 3.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 113,607 shares of the medical equipment provider's stock after selling 4,400 shares during the period. Candriam S.C.A. owned approximately 0.16% of Lantheus worth $10,163,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of LNTH. Wilmington Savings Fund Society FSB bought a new stake in Lantheus during the 3rd quarter valued at approximately $25,000. Kestra Investment Management LLC bought a new stake in shares of Lantheus during the fourth quarter valued at approximately $27,000. UMB Bank n.a. grew its stake in Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares during the period. World Investment Advisors LLC bought a new position in Lantheus in the third quarter worth $60,000. Finally, RiverPark Advisors LLC purchased a new position in Lantheus during the third quarter valued at $74,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Stock Down 4.9 %

Shares of Lantheus stock traded down $5.39 on Tuesday, reaching $104.62. The company's stock had a trading volume of 1,345,441 shares, compared to its average volume of 945,884. Lantheus Holdings, Inc. has a 52 week low of $56.44 and a 52 week high of $126.89. The firm's fifty day simple moving average is $91.13 and its two-hundred day simple moving average is $96.88. The company has a market capitalization of $7.16 billion, a price-to-earnings ratio of 17.41 and a beta of 0.38.

Remove Ads

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several research reports. Truist Financial increased their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. JMP Securities reiterated a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $132.86.

Insider Buying and Selling

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company's stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.